Q-omics provides the consensus-scored SNORD11 profile across patient tissues and cancer cell-line models. SNORD11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SNORD11 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, SNORD11 RNA expression shows 13,155 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, LUAD, and UVM as cancer lineages where SNORD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD11 survival associations across molecular data types. SNORD11 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD11 RNA expression–survival associations across cancer types. High SNORD11 expression shows unfavorable associations in UCEC, KIRC, UVM, CESC, THYM and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SNORD11 RNA expression.
This table summarizes SNORD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD11 shows lower tumor expression in THCA and higher tumor expression in LUAD, COAD, CHOL, ESCA and STAD. The LUAD box plot shows higher SNORD11 RNA expression in tumor versus normal tissue (log2 FC = +0.714, t-test p < 0.001).
This table shows molecular features associated with SNORD11 in patient tissues and cancer cell lines. In patient samples, SNORD11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
